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Objectives—To pilot a pharmacist-led, patient centered medication management program.
Design—Prospective, single arm trial.
Setting—Academic geriatric psychiatry outpatient clinic.
Participants—Outpatients at least 65 years old, proxy available if demented, and on two or more
psychiatric medications.
Intervention—A clinical pharmacist completed a baseline medication review and made
evidence-based recommendations that were implemented by the pharmacist after discussion with
the physician. The pharmacist made a minimum of monthly contact for 6 months to review
medications and related issues.
Measurements—The primary outcome was the change in number of medication related
problems over time (3 and 6 months) as defined by a predetermined classification system.
Results—The mean age of the 27 patients was 75 years, 10 of whom required a proxy to
participate. On average, patients had 9 chronic conditions and were taking 14 medications. The
mean number (SD; range) of medication related problems at baseline was 4.1 (2.2; 0–8,) and at 3
and 6 months were 3.6 (2.4, 0–9) and 3.4 (2.1; 0–8), respectively. Most follow-up problems were
new (80% and 89% at 3 and 6 months, respectively).
Conclusion—Using a pharmacist to deliver a medication management program was feasible and
addressed existing problems. However, new problems developed over a short interval (3–6




Compared to younger adults, older adults (≥65 years) take more medications, have more
medication-related negative outcomes, and utilize more health services (1). Older adults
with psychiatric disease have even more pronounced risks because psychoactive drugs are
disproportionately associated with delirium, falls, and adverse drug interactions (2).
Psychiatric settings are not typically equipped to provide global medication review and
management, despite treating older patients with extensive comorbidity and complex
medication regimens.
Pharmacist-led interventions have improved the quality of medication use in many
settings(3). Pharmacists can improve patients’ outcomes by monitoring symptoms,
counseling, resolving medication-related problems, encouraging adherence to medications,
and facilitating communication with physicians. To our knowledge, such interventions have
never been evaluated among older psychiatric outpatients, a vulnerable and medically
complex group of patients. The purpose of this study was to pilot test a novel pharmacist-led
medication management program that specifically targets older psychiatric outpatients.
Watson et al. Page 2























This pilot study tested a 6-month, pharmacist-led medication management program on
medication-related problems at 3 and 6 months. The details of this study have been
described previously (4) and are summarized here. The UNC Biomedical Institutional
Review Board, Chapel Hill, North Carolina, approved the study.
Setting and participants
Participants were recruited from an academic geriatric psychiatry outpatient clinic.
Eligibility criteria included: current enrollment in the clinic for any diagnosis, age ≥65 years,
English speaking, not in hospice care, and being prescribed ≥2 central nervous system
(CNS)-active medications. In addition, a proxy had to be available if the patient had a
diagnosis of dementia or screened positive for cognitive impairment on a 6-item cognitive
screen(5). The rationale for involving a proxy was not only to assure appropriate consent,
but also to target the person most responsible for managing the patient’s medications.
Data Collection Process and Measures
Patients were evaluated at baseline, 3 months and 6 months. Informed consent was obtained,
including assent from patients when a proxy was indicated. The baseline visit consisted of
an interview with the research assistant (RA) and a comprehensive medication review with
the clinical pharmacist. Detailed methods are reported elsewhere (4), but included chart-
based information on psychiatric diagnoses, health care utilization, and medication
adherence determined by a direct pharmacist clinical assessment (6). When a proxy
consented, the proxy reported on the patients’ medication adherence.
Intervention
The clinical pharmacist initiated a multi-faceted medication evaluation and management
intervention that involved close collaboration with the patient’s primary physician. The
medication evaluation and intervention occurred face-to-face at baseline; subsequent
evaluations and interventions occurred via telephone. The intervention was patient-centered
and took into account patient preferences for care (7).
Medication-related problems—The clinical pharmacist’s assessments were guided by a
list of medication-related problems developed by study investigators following an extensive
review of the literature and subsequent refinement of previous work(4). The potential
medication-related problems are described in the footnote to Figure 1. This approach to
formulating assessments of quality medication use was developed specifically to be
practical, comprehensive, and amenable to clinical practice. Upon completion of the
comprehensive medication review and medical record review, the clinical pharmacist
formulated a written assessment of the quality of medication use along with a proposed plan.
Recommendations and plan of care—Recommendations were communicated to the
primary care physician and other relevant prescribers. The preferred method of
communication was via phone; however, if the pharmacist could not reach the physician by
phone following several attempts, the assessment and plan were faxed to the physician’s
Watson et al. Page 3






















office. The faxed note requested that the physician indicate his/her acceptance, rejection, or
revision to the proposed plan and return the fax or phone call to the pharmacist. The final
plan for addressing medication-related problems was developed collaboratively with the
provider to ensure coordination and continuity of care.
All patients/proxies received a call from the clinical pharmacist informing them of the
assessment and plan for improving their medication use. Additionally, all physician-
approved medication changes were discussed in detail with the patient/proxy, including how
changes would be made. For example, if the change involved purchase of a nonprescription
medication, the pharmacist instructed the patient/proxy as to where they could obtain the
new product, what exactly to look for, and instructions regarding its use. The clinical
pharmacist also provided education, including the purpose, proper use, anticipated response
to therapy, and potential adverse effects of each medication. Regardless of who was
responsible for implementing the medication changes, the clinical pharmacist provided the
educational component by phone. All patients/proxies were mailed a written summary of the
medication assessment and plan. When mailing the written summary, the clinical pharmacist
also provided the patient with a personal medication record. The personal medication record,
developed by study investigators, contained an up-to-date listing of all medications the
person was to be taking (prescription, nonprescription, complementary and alternative),
including strength, frequency, instructions for use, and indication.
A key component of the intervention was documentation of the comprehensive medication
review, with final assessment and plan. This documentation took the form of a traditional
SOAP (subjective, objective, assessment, plan) note and was either entered directly into the
patient’s electronic medical record, or, if the patient’s primary care records were located
elsewhere, faxed to the physician’s office. Moreover, documentation included attention to
medication reconciliation among all providers; the clinical pharmacist updated the
medication records for all patients in the electronic medical record system and, when faxing
notes to physician offices, called attention to the need to update the patient’s medication list.
Follow-up—Finally, the clinical pharmacist followed the patient for 6 months, providing
periodic medication evaluation and management by phone. All patients/proxies received
monthly follow-up phone calls to evaluate the potential for ongoing or new medication-
related problems and address any medication-related questions. Where needed and in
collaboration with the physician, the clinical pharmacist intervened to resolve medication-
related problems over the 6-month period. All encounters with a patient were documented in
the study database.
Outcome assessments
A second pharmacist provided independent assessments of medication-related problems at 3
and 6 months. Although the second pharmacist did not communicate with the clinical
pharmacist when assessing medication-related problems, she did have access to the clinical
pharmacist’s assessment and recommendations in the electronic medical record. An
adjudication process was used by the study team to assure consensus when applying the
medication-related problem framework and making recommendations. A third pharmacist
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and one physician also reviewed a random sample of patient records at all three visits to
confirm the appropriate use of the framework.
Data Analysis
Descriptive statistics, means, standard deviations (SD) and ranges for continuous data and
frequencies and percentages for categorical data, were calculated. Poisson mixed models
(random intercept) were used to assess a trend over time in the primary outcome of
medication related problems at 3 and 6 months.
RESULTS
Of 173 adults assessed for inclusion, 146 were not eligible (n=63), reachable (n=25), or
interested (n=58) in participating. Twenty-seven patients completed the baseline interview
and one patient died shortly after enrollment due to unanticipated complications from
prostate cancer, leaving 26 participants who completed the 3 and 6 month interviews. Of the
baseline patients, 10 (37%) were cognitively impaired, requiring proxies to take part in
medication discussions on their behalf. Patients were on average 75 years of age (SD 8.1),
mostly female (n=17, 63%), white (n=20, 74%), educated (93% had at least HS degree), and
had multiple chronic conditions (mean 8.7, SD 2.8). With regard to psychiatric diagnoses
documented in the chart, 20 (74%) listed depression, 9 (33%) anxiety, 9 (33%) dementia and
3 (11%) bipolar disorder (these were not mutually exclusive). The mean number of
medications was 14.0 (SD 4.7) (including over-the-counter and herbal medications) and
each participant had a mean of 3 (SD 1.0) prescribers.
At baseline each participant had a mean of 4.1 (SD 2.2) medication-related problems. There
was not a significant decrease in overall problems over time (3 months: mean 3.6, SD 2.4; 6
months: mean 3.4, SD 2.1). Baseline problems tended to resolve (3 months: mean 0.7, SD
1.0; 6 months: mean 0.4, SD 0.9), but were replaced by new problems at the 3 (mean 2.0,
SD 2.0) and 6 month (mean 3.0, SD 2.1) visits. Figure 1 displays the breakdown of these
problems by category over time. Suboptimal medication use, suboptimal dose and potential
problem were most prevalent at baseline, with potential problem and suboptimal drug
improving over time. Non-adherence, while seen in 14% of participants at baseline, rose to
34% and 33% at 3 and 6 months respectively, while the total number of medications did not
change over time. Visits to the Emergency Department or transfers to higher levels of care
did not change relative to the self-reported 6 months prior to the intervention. During
follow-up phone calls with the patients, only one potential problem was identified regarding
a duplicate order for a patient who had a transition in care.
CONCLUSIONS
This pilot study tested a novel medication management program designed to improve the
quality of medication use in vulnerable older adults who receive outpatient care from
psychiatrists. On the primary outcome of medication-related problems over time, there was
no change in the overall number of medication related problems at 3 or 6 months. As a pilot
study, we were not powered to detect this difference. There was no change in health service
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utilization or transfers to higher levels of care compared to the 6 months prior to the study.
The intervention proved feasible in the psychiatric clinic.
This study extends a framework for defining medication related problems in older adults and
provides preliminary data on a novel intervention for addressing them. We learned that
despite a comprehensive patient-centered evaluation and initial improvement in medication
quality following one visit, medication-related problems were present six months later. One
likely possibility is that new and different problems arose over time, rather than the
persistence of problems identified at baseline. It may be that a control group would have
developed more problems over time and that the unchanged number of problems as reflected
in our outcome is in fact a sign of stability. A longer follow-up may have been required to
observe a reduction in the number of medication-related problems identified. Alternatively,
because monthly follow-up was done by phone, interventions by the clinical pharmacist may
have had less impact compared to face-to-face intervention at baseline, where direct
observation of medications and measures of adherence could be verified. The nature of the
phone calls was brief and not standardized in this study, mostly offering an opportunity for
the patient to ask any questions about their medications, and questions were few. The
categories of problems that occurred over time, while limited in power, offer hints as well,
showing that adherence to medications worsened over time but use of suboptimal
medications decreased over time balancing out the total number of problems. Possible
reasons for non-adherence include that new medications were introduced, that there was a
different pharmacist assessing for adherence for follow-up visits and that these were done by
phone instead of face-to-face, and it is possible that patients became more fearful of their
medications when the pharmacist described them in detail.
This study has the inherent limitations of a pilot design, specifically in its lack of a control
group and small size. In addition, despite our attempt to provide a systematic adjudication
regarding the number of medication problems over time, the second pharmacist may have
identified problems with a different level of scrutiny, reflecting a potential detection bias.
Despite these limitations, this report provides important findings. The patients in this study
had multiple chronic diseases and were on an average of 14 medications, highlighting a high
burden of illness. While aging experts have long realized the special needs of complex
patients and the potential benefits of pharmacist-delivered interventions (2), this is the first
report to our knowledge of such a comprehensive and patient-centered medication
management program in geriatric psychiatry. Using a clinical pharmacist to deliver a
medication management program in this specialty setting was feasible and addressed
existing problems. However, new problems developed over a short interval (3–6 months),
suggesting that ongoing intervention is required.
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Distribution of Medication-Related Problems by Type of Problem Over Time
Medication-related Problems Definition
Suboptimal medication The individual is receiving a drug that has no indication, is not effective, or is
potentially not safe (i.e., risk of using drug outweighs benefit).
Suboptimal dose The individual is taking an appropriate medication, but the dose is not optimal to
achieve desired response, or has the potential for harm.
Adverse drug events The individual is experiencing adverse consequences attributed to a drug or the
inappropriate use of a drug.
Nonadherence The individual has not filled a prescription, is not taking a drug, or is not using a
drug as prescribed, whether intentional or unintentional (determined by direct
pharmacist clinical assessment).
Less costly alternative available The individual is prescribed a medication, for which a less costly, equally effective
and safe drug is available, and preferred by the patient, but the patient is receiving a
more expensive product; or the patient could benefit from prescription assistance,
but is not receiving the benefit and desires to.
Undertreatment The individual has a medical condition that would benefit from drug therapy (clear
indication) and the patient has no contraindications to the drug, but the drug was not
prescribed.
Medication monitoring needed The individual is receiving a drug and monitoring is required to assess response to
therapy or prevent harm, but has not been done.
Potential problem There is a potential medication-related problem warranting physician referral and
further evaluation. The potential problem cannot be classified as a medication-
related problem without further physician evaluation of the problem.
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